Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Liwei DengYanyuan SunHaiqing WangChangli LiaoDeshan LiGuohui XuXuegang Yang

Published in: Journal of hepatocellular carcinoma (2024)

In comparison with TACE plus donafenib, TACE plus donafenib with ICIs could significantly improve DCR, PFS, and OS as a potential first-line treatment for unresectable HCC with an acceptable safety profile.

Keyphrases

liver metastases
locally advanced
radiofrequency ablation
rectal cancer
radiation therapy
risk assessment
climate change
data analysis